Anebulo Pharmaceuticals Inc

NASDAQ:ANEB   12:52:20 PM EDT
7.01
+0.01 (+0.14%)
Regulatory, Earnings Announcements

Anebulo Pharmaceuticals Says On Track To Commence Phase 2 Proof-Of-Concept Clinical Trial With Aneb-001 In Q4

Published: 06/21/2021 20:19 GMT
Anebulo Pharmaceuticals Inc (ANEB) - Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results.
Anebulo Pharmaceuticals Inc - Remains on Track to Commence Phase 2 Proof-of-concept Clinical Trial With Aneb-001 in Q4 of 2021.
Anebulo Pharmaceuticals Inc - Cash and Cash Equivalents Were $3.3 Million As of March 31, 2021.
Anebulo Pharmaceuticals - Ipo Net Proceeds Provide Adequate Funding for Co's Planned Business Operations and Clinical Studies Through Dec 31, 2022.
Anebulo Pharmaceuticals Inc - Anticipates Topline Results From Phase 2 Proof-of-concept Clinical Trial With Aneb-001 in First Half of 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.03

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.03

More details on our Analysts Page.